2月2日，迈瑞医疗跌1.14%，成交额12.59亿元。两融数据显示，当日迈瑞医疗获融资买入额1.48亿元， 融资偿还1.65亿元，融资净买入-1677.63万元。截至2月2日，迈瑞医疗融资融券余额合计43.36亿元。 融资方面，迈瑞医疗当日融资买入1.48亿元。当前融资余额42.87亿元，占流通市值的1.89%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，迈瑞医疗2月2日融券偿还700.00股，融券卖出4800.00股，按当日收盘价计算，卖出金额 89.81万元；融券余量25.91万股，融券余额4848.00万元，超过近一年80%分位水平，处于高位。 截至9月30日，迈瑞医疗股东户数10.88万，较上期增加18.86%；人均流通股11139股，较上期减少 15.87%。2025年1月-9月，迈瑞医疗实现营业收入258.34亿元，同比减少12.38%；归母净利润75.70亿 元，同比减少28.83%。 分红方面，迈瑞医疗A股上市后累计派现353.36亿元。近三年，累计派现250.25亿元。 机构持仓方面，截止2025年9月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持 ...

Core Insights - The public REITs market in China is expanding from infrastructure to commercial real estate, marking a new phase of development as per the announcement by the China Securities Regulatory Commission (CSRC) on December 31, 2025 [5][6][18] - The announcement defines commercial real estate REITs and outlines requirements for fund registration, management, and regulatory responsibilities, while still adhering to previous guidelines for infrastructure securities [5][6] - The first batch of commercial real estate REITs is expected to raise a total of 31.47 billion yuan, covering various commercial formats such as hotels, office buildings, and shopping centers [7][18] Summary by Sections Commercial Real Estate REITs Overview - The CSRC's announcement on December 31, 2025, signifies the dual development of commercial real estate and infrastructure REITs in China [5] - Commercial real estate REITs are defined as closed-end public funds that invest in commercial real estate asset-backed securities to acquire ownership or operational rights, generating stable cash flows from rents and fees [5][6] Regulatory Framework - The new business guidelines include the expansion of applicable scope to include commercial real estate REITs, with specific requirements for operational and financial disclosures [6] - Funds raised through public REITs can be used for acquiring existing assets, new investments, debt repayment, and working capital, but not for purchasing residential land [6] Initial Batch of REITs - Eight commercial real estate REITs have been submitted for approval, with expected fundraising ranging from 1.703 billion yuan to 7.47 billion yuan [7][8] - The underlying assets for these REITs are primarily located in core urban areas, with operational performance generally strong [7] Specific REITs Details - **Hua'an Jinjiang REIT**: Expected to raise 1.703 billion yuan, focusing on 21 hotels across 18 cities, with an average occupancy rate of 61.58% [8] - **Huitianfu Shanghai Real Estate REIT**: Expected to raise 4.002 billion yuan, with two office buildings in Shanghai showing a 100% occupancy rate [9] - **CICC Vipshop REIT**: Expected to raise 7.47 billion yuan, focusing on two outlet projects with high operational performance [10] - **Hua'an Lujiazui REIT**: Expected to raise 2.810 billion yuan, with assets including office and commercial projects in Shanghai [11] - **Hua'an Poly Development REIT**: Expected to raise 2.093 billion yuan, with assets in Guangzhou and Foshan [12] - **Hua'an Yintai REIT**: Expected to raise 4.2785 billion yuan, focusing on a shopping center in Hefei [13] - **Hua'an CapitaLand REIT**: Expected to raise 4.054 billion yuan, with assets in Shenzhen and Mianyang [14] - **Guotai Haitong Sasseur REIT**: Expected to raise 5.064 billion yuan, focusing on an outlet project in Xi'an [15] Market Potential - The commercial real estate sector in China has a substantial existing asset base, with over 9,000 retail properties and a total area exceeding 667 million square meters [18] - The introduction of commercial real estate REITs is expected to enhance asset liquidity and broaden financing channels for companies [18] Investment Recommendations - Companies that have proactively assessed and prepared for REIT issuance, such as Poly Development and Maoye Commercial, are likely to have a competitive advantage [19] - Focus on firms with stable and mature assets, such as China Resources Land and China Overseas Development, for potential investment opportunities [19]

Group 1: ETF Performance - As of February 2, 2026, the Medical Equipment ETF (159873) had a turnover of 5.82% with a transaction volume of 14.6087 million yuan, while the tracked index, the CSI All Share Healthcare Equipment and Services Index (H30178), fell by 1.44% [1] - The Medical Equipment ETF (159873) saw a net subscription of 11 million shares during the trading session [2] - The Biopharmaceutical ETF (159859) had a turnover of 3.87% with a transaction volume of 142 million yuan, and the corresponding index, the National Biopharmaceutical Index (399441), decreased by 2.18% [2] Group 2: Fund Flows - The Medical Equipment ETF (159873) experienced a net inflow of 4.2585 million yuan, with a total of 22.8076 million yuan net inflow over the last five trading days [2] - The Biopharmaceutical ETF (159859) achieved a new high in scale at 3.705 billion yuan and a new high in shares at 9.396 billion shares as of January 30 [3] - The Biopharmaceutical ETF (159859) has seen continuous net inflows over the past ten days, totaling 425 million yuan [3] Group 3: Sector Insights - The Medical Equipment ETF (159873) has a high content of brain-computer interface technology, accounting for over 17%, indicating strong technological attributes [3] - The overall industry landscape for medical devices is improving, with leading companies showing performance recovery in Q3, suggesting potential for future capital inflows [6] - The innovative drug sector is expected to see a recovery phase, with a focus on domestic innovation and increased global participation, indicating a positive outlook for investment opportunities [7]

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

2025年广东省深圳市南山区迈入"万亿城区"，成为全国首个GDP过万亿元的地市辖区。作为城市运转 的"动力源"、经济发展的"生命线"，南方电网深圳供电局以务实举措优服务、保民生、强基建。 据统计，"十四五"期间，南山区全社会用电量从100.71亿千瓦时跃至132.72亿千瓦时，增长31.78%； 2025年，平均每度电支撑南山区创造GDP超75元。可靠电力为南山区全面建设全球一流现代化创新城区 提供了坚实支撑。 "充足电"撬动"大产值" 在深圳南山这片民营企业成长的沃土上，孕育和培养出腾讯、华为、中兴、大疆、迈瑞等一批知名企 业。截至目前，南山区市场主体达63.7万个，上市企业总数达218家，密度保持全国第一。 2025年，全国首家民营企业用电营商环境服务中心在南山区揭牌成立，为民营企业提供"一站式、全周 期、个性化"服务。深圳南山供电局用好政企用电用能共享服务平台，全面推广高压业扩"免申即享"服 务。去年，该局完成高压业扩245项，投产容量68.83万千伏安，同比增长16.3%，为深圳"工业上楼"示 范项目——南山智造红花岭产业园等重大项目增加动能，并收获了字节跳动、大疆、百度、中兴通讯等 企业好评。 优质 ...

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...

Group 1 - The report highlights that the non-ferrous metal sector is expected to benefit from the resonance between financial attributes and industrial trends, with short-term adjustments potentially providing mid-to-long-term investment opportunities [11][12] - The report notes that the A-share market is experiencing significant internal differentiation, with a potential shift in rhythm following the spring rally, although a major level switch has not yet occurred [13][14] - The report indicates that the U.S. interest rate cut cycle is not yet over, and after the current risk factors are released, the U.S. Treasury market may return to a downward yield trend [4][18] Group 2 - The manufacturing PMI for January indicates a decline in both supply and demand indices, with the manufacturing sector's sentiment falling into contraction territory [21][22] - The report discusses the government's new policy to optimize and expand service supply, aiming to enhance service consumption and support economic growth through structural reforms [29][30] - The transportation sector is projected to gradually enter a profitability cycle, with significant growth expected in air cargo demand and advancements in low-altitude economy initiatives [34][35] Group 3 - The report emphasizes the importance of service consumption, which is expected to continue growing, supported by favorable policies and structural improvements in supply [31][32] - The logistics sector is highlighted for its rapid growth, with significant advancements in automated delivery systems and international market expansion opportunities [36] - The report suggests investment opportunities in various sectors, including logistics, aviation, and low-altitude economy, indicating a positive outlook for these industries [36][37]

Summary of Key Points from Conference Call Records Industry Overview - **Surgical Robot Industry**: The Chinese surgical robot industry is experiencing rapid development, supported by national policies and capital investment. Key technological advancements include remote operation, miniaturization, and AI assistance. The market for laparoscopic surgical robots is projected to reach 40.543 billion yuan by 2033, with a CAGR of 28.7% from 2024 to 2033 [doc id='21'][doc id='19']. Core Insights and Arguments - **Investment Opportunities in Innovative Drugs and CRO**: Despite past challenges, investment activity in innovative drugs and Contract Research Organizations (CRO) is expected to rise significantly. Business development (BD) amounts are anticipated to reach new highs, with companies like Rongchuang and Shiyao achieving attractive upfront payment ratios [doc id='3'][doc id='4']. - **Medical Device Sector Recovery**: The medical device sector is nearing the end of its inventory destocking phase, with performance expected to improve gradually in 2026. The resumption of procurement rhythms and an increase in bidding volumes are noted trends [doc id='5']. - **IVD Sector Outlook**: The In Vitro Diagnostics (IVD) sector is expected to face pressure in 2025, but conditions are projected to improve in 2026 as pricing pressures ease and policies are fully implemented [doc id='8'][doc id='9']. - **Traditional Chinese Medicine (TCM) Recovery**: The TCM sector is anticipated to bottom out in Q2 2026, with a potential recovery in 2027 driven by policy support and demand resurgence [doc id='10']. Additional Important Insights - **AI Medical and Brain-Computer Interface Technologies**: AI in healthcare is crucial for enhancing productivity, though its commercialization path remains uncertain. The brain-computer interface sector shows promise but also faces commercialization challenges [doc id='6']. - **CRO Sector Performance**: The CRO sector is showing strong order and operational performance, with companies like Kanglong Huacheng making significant progress in commercial production [doc id='11']. - **Market Dynamics for Surgical Robots**: The market for surgical robots is transitioning from an introduction phase to a growth phase, with increasing sales but slower revenue growth, indicating a structural transformation [doc id='19']. - **Regulatory Developments**: The National Medical Insurance Administration's guidelines are expected to accelerate the clinical application of surgical robots by establishing legitimate billing items [doc id='19']. Company-Specific Highlights - **Shiyao Group and AstraZeneca Collaboration**: The collaboration in the weight loss and metabolism field has set historical highs for upfront payments and total package amounts, although the overall sentiment in the sector remains subdued [doc id='7']. - **Kanglong Huacheng's Growth**: The company is expected to see a significant increase in order retention rates with the launch of its Shaoxing Phase II project, enhancing its competitive position in the CRO market [doc id='12']. - **Emerging Companies**: Companies like Tianyu and Starly are projected to enter performance inflection points this year, with significant growth potential in the raw material pharmaceutical sector [doc id='13'][doc id='14']. This summary encapsulates the key points from the conference call records, highlighting the current state and future outlook of various sectors within the healthcare and pharmaceutical industries in China.

Core Viewpoint - The China Securities Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index (931000) experienced a decline of 0.80% as of January 30, 2026, with mixed performance among constituent stocks [1]. Group 1: Index Performance - The Greater Bay Area ETF (512970) fell by 1.24%, with the latest price at 1.52 yuan [1]. - Over the past six months, the Greater Bay Area ETF has accumulated a rise of 17.78% [1]. - The ETF's net value increased by 64.66% over the past two years [1]. Group 2: Return and Risk Metrics - The maximum drawdown for the Greater Bay Area ETF this year is 3.62%, with a relative benchmark drawdown of 0.02% [2]. - The ETF's management fee is 0.15%, and the custody fee is 0.05% [2]. - The ETF achieved a maximum monthly return of 21.99% since inception, with the longest consecutive monthly gain being 5 months and a maximum cumulative gain of 32.62% [1]. Group 3: Tracking Accuracy and Composition - The tracking error for the Greater Bay Area ETF over the past three months is 0.022% [3]. - The index closely tracks the performance of companies benefiting from the development of the Guangdong-Hong Kong-Macao Greater Bay Area [3]. - The top ten weighted stocks in the index account for 44.55% of the total weight, including China Ping An, Luxshare Precision, BYD, and others [3][5].

Core Viewpoint - The event "For China's Economy, Cheers to Entrepreneurs" highlighted the emergence of a new generation of entrepreneurs in China, focusing on advanced technologies such as brain-machine interfaces, autonomous driving, and low-altitude economy, showcasing their impact on society and the economy [1][3][29]. Group 1: Technological Innovations - Strong Brain Technology's smart bionic hand has assisted over 10,000 individuals with upper or lower limb disabilities, allowing them to live and work normally [29]. - The L4 autonomous vehicle from Pony.ai operates without a driver, demonstrating advancements in autonomous driving technology [29]. - The flying car developed by Huitian has received 7,000 global orders and plans to start deliveries by the end of 2026, with a next-generation model capable of carrying six people for 500 kilometers [29]. Group 2: New Quality Entrepreneurs - The 2025 "Top Ten Economic Figures" includes four entrepreneurs associated with cutting-edge technologies: Liu Debing from Zhipu, Peng Jun from Pony.ai, Han Bicheng from Strong Brain Technology, and Zhao Deli from Huitian [31]. - The evaluation committee also recognized groups involved in "China's Chip Infrastructure," highlighting the shift towards new quality productivity driven by technological breakthroughs and innovative resource allocation [31][32]. Group 3: Economic Strategy and Consumer Focus - The "14th Five-Year Plan" emphasizes enhancing the competitiveness of traditional industries while promoting new demand to drive supply [32]. - Three representatives from the consumer and lifestyle sector were recognized: Leng Youbin from China Feihe, Ma Yin from Anaya, and Wu Xiangdong from Zhenjiu Lidu Group [32]. Group 4: Historical Context of Entrepreneurs - The evolution of Chinese entrepreneurs has gone through 15 stages since the reform and opening up, from the emergence of individual private economies to the current focus on high-quality development and innovation [35][36][37]. - The current entrepreneurial landscape is characterized by a significant shift towards new quality productivity, with a focus on advanced manufacturing and technology-driven solutions [51]. Group 5: Future Outlook - The future of China's economy is expected to continue along the path of high-quality development, leveraging new technologies and innovative business models [52]. - The "single person + AI as a company" model represents a new entrepreneurial path empowered by technology, indicating a shift in how businesses operate and innovate [52].